Scott Greenfeder, Ph.D is currently serving as the Vice President of Global Regulatory and In-Vitro Diagnostic Strategy for the oncology portfolio at Bayer, a position he has held since June 2024. Scott previously held the role of Oncology Regulatory Affairs Strategy Group Head from July 2018 to June 2024.

Before joining Bayer, Scott worked at Daiichi Sankyo, Inc., where he served as Executive Director of Regulatory Affairs Strategy for Specialty Medicine R&D and held several other senior roles. His career also includes significant positions at Regeneron Pharmaceuticals, Merck, and Schering-Plough Research Institute, where he focused on regulatory strategy, submissions, and innovative research in various therapeutic areas, including cardiovascular/metabolic diseases and allergy.

Scott began his academic journey as a Graduate Student at UMDNJ-New Jersey Medical School, where he studied DNA replication, and later completed a Post-Doctoral Fellowship at Hoffmann-La Roche, focusing on inflammation and autoimmune diseases.

With over three decades of experience in the pharmaceutical industry, Scott is dedicated to advancing regulatory strategies that enhance patient access to groundbreaking therapies.